Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

August 1, 2024 7:00 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.JNJ-2113 is the first- and only-in-class targeted oral peptide inhibitor of the IL-23 receptor in clinical development. Based on...

Read more

OMS360 Appoints Dr. Joshua Everts as Chief Clinical Officer

August 1, 2024 7:00 AM

ATLANTA, GA / ACCESSWIRE / August 1, 2024 / OMS360 has appointed Joshua Everts, DDS, MD, a distinguished oral and maxillofacial surgeon, as the organization's first Chief Clinical Officer. In this new role, Dr. Everts will lead collaboration between surgeons, continuing education, and mentoring opportunities. He will also serve as the direct funnel of partner doctors' voices to champion clinical quality and effectiveness, advance a culture of...

Read more

Bausch Health Announces Second Quarter 2024 Results

August 1, 2024 7:00 AM

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health...

Read more

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

August 1, 2024 6:30 AM

SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate and independent research reports have been published by industry analysts on the Company."NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy," is the title of a new research note published by David...

Read more

Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 1, 2024 6:30 AM

CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs. We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.," said Stéphane Bancel, Chief Executive Officer of...

Read more

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET

August 1, 2024 6:30 AM

ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Wednesday, August 14, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ended June 30, 2024. A...

Read more

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

August 1, 2024 5:20 AM

MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development, is pleased to report that it has appointed Haywood Securities Inc. ("Haywood") to act as strategic advisor to the Company to support its near-term objectives.Haywood's services will focus on assisting the Company to secure potential strategic level investment and transactions with strategic...

Read more

Syringe and Needle Industry in GCC Is Expected to Reach USD 1,164.90 Million by 2034 And Grow at A Compound Annual Growth Rate of 5.40% | Future Market Insights, Inc.

August 1, 2024 2:20 AM

The demand for syringes and needles in GCC countries is predicted to surge at a 5.40% CAGR through 2034. According to the estimates, the syringe and needle industry in GCC is valued at USD 688.5 million in 2024 and is projected to surpass USD 1,164.90 million by 2034.In the Gulf Cooperation Council (GCC) countries, the syringe and needle industry is undergoing shifts due to digital health technologies' introduction. Technological upgraded...

Read more

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024

July 31, 2024 4:05 PM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be...

Read more

The Siegel Rare Neuroimmune Association Kicks Off Awareness Campaign

July 31, 2024 2:00 PM

Campaign launched on the date organization president's wife developed symptoms of transverse myelitisPOWELL, OH / ACCESSWIRE / July 31, 2024 / Rare neuroimmune disorders can happen without warning and have devastating, lifelong effects. This was the case for Pauline Siegel. On July 31, 1994, she collapsed with intense pain in her lower back and soon was completely paralyzed below her waist. Pauline spent several days in the hospital and was...

Read more

Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications

July 31, 2024 12:00 PM

ALLEN, TX / ACCESSWIRE / July 31, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the "Company") announced today that the Company and the Department of Immunology, Bulgarian Academy of Science The Stephan Angeloff Institute of Microbiology have initiated a cooperative effort to expand the use of each other's technology.The main area of research by the Department of Immunology, through its seven state of the art laboratory facilities,...

Read more

Zynex Inc. CEO Thomas Sandgaard Discusses Significant Company Growth and Future Innovations

July 31, 2024 11:40 AM

VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / Zynex Inc. CEO Thomas Sandgaard joined Steve Darling from Proactive to announce the company's financial and operational results for the second quarter ending June 30, 2024, in an interview with Proactive. The company achieved a remarkable 20% year-over-year increase in orders, marking the ninth consecutive quarter of record-breaking order numbers. Zynex reported an 11% year-over-year increase in...

Read more

Kaelin Drakeford Teams Up with ZetrOZ Systems as Brand Ambassador

July 31, 2024 10:15 AM

The football star finds that ultrasound treatment with the sam® sustained acoustic medicine device facilitates recovery and peak performance.TRUMBULL, CT / ACCESSWIRE / July 31, 2024 / Kaelin Drakeford, starting safety for his football team, was feeling shoulder pain after practices for the upcoming season. He found relief and healing from treatments with the sam® wearable ultrasound unit from ZetrOZ Systems - and that positive experience led...

Read more

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

July 31, 2024 10:00 AM

Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that the European Patent Office has issued a new patent to Napo for methods of preventing, ameliorating and/or treating diarrhea associated with congenital diarrheal disorders (CDDs) using a proanthocyanidin polymer composition such as crofelemer, Napo's novel plant-based prescription drug."We are very happy that this patent has been issued and...

Read more

Syra Health Wins Contract Valued At Nearly $6M To Train Indiana Health Workers

July 31, 2024 9:40 AM

Syra Health Corp. (NASDAQ:SYRA), has been awarded a $5.8 million contract to train professionals who deliver healthcare to Indiana residents at home or in a community-based setting under the purview of the Indiana Family and Social Services Administration (FSSA). Headquartered in Carmel, Indiana, Syra Health was founded in 2020 and is focused on improving healthcare through innovative services and technology solutions. At its core, the company...

Read more

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

July 31, 2024 9:15 AM

Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I spaceNEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief...

Read more

Following Sale to New Owners, Eye Care Leaders Becomes Sightview Software and Commits Additional Investment to All Products

July 31, 2024 9:00 AM

RALEIGH, NC / ACCESSWIRE / July 31, 2024 / Following its successful sale to new owners, Eye Care Leaders, a leading software provider for eye care practices nationwide, is committing significant additional resources to improve and support all products and changing its name to Sightview Software. Sightview Software Logo Under Sightview Software, all products and services formerly owned by Eye Care Leaders will be supported indefinitely, with...

Read more

Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press

July 31, 2024 9:00 AM

Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows individuals and companies to produce specialized mushroom ingredients such as psilcybin, has been nominated as "Best New Product of 2024" by the Santa Monica Daily Press (SMDP).Prototype of the Hypha Labs bioreactor A prototype of the Hypha Labs bioreactor In the article, the Santa Monica...

Read more

Med-X Engages With Full-Service Investment Banking Firm Maxim Group

July 31, 2024 8:31 AM

Med-X, Inc., a leading innovator of all-natural green scene solutions addressing the pest control, health and wellness markets, today announced that it has engaged Maxim Group - a full-service investment bank - as its financial advisor to assist the Company in articulating its growth strategy to the investment community with the ultimate goal of a listing on a U.S. National Exchange, such as the Nasdaq Stock Exchange or the New York Stock...

Read more

Inspire Veterinary Partners to Present at Sidoti Virtual Investor Conference August 14

July 31, 2024 8:00 AM

Inspire Veterinary Partners, Inc. (NASDAQ:IVP) ("Inspire" or the "Company"), an owner and provider of pet health care services throughout the U.S., today announced that Kimball Carr, President & Chief Executive Officer of Inspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 14th at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here:...

Read more